{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T14:02:29Z","timestamp":1761228149987,"version":"build-2065373602"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,23]]},"DOI":"10.7759\/cureus.95219","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T13:47:55Z","timestamp":1761227275000},"source":"Crossref","is-referenced-by-count":0,"title":["Dupilumab-Induced Psoriasis in a Patient With Chronic Rhinosinusitis With Nasal Polyps: A Case Report"],"prefix":"10.7759","author":[{"given":"Rehab","family":"Simsim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffery","family":"Cowger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leigh","family":"Sowerby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000031031","article-title":"Subgroups in the treatment of nasal polyposis with dupilumab: a retrospective study","volume":"101","author":"Bertlich M","year":"2022","unstructured":"Bertlich M, Freytag S, Dombrowski T, et al.. Subgroups in the treatment of nasal polyposis with dupilumab: a retrospective study. Medicine (Baltimore). 2022, 101:31031. 10.1097\/MD.0000000000031031","journal-title":"Medicine (Baltimore)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2018.1449642","article-title":"Dupilumab for treatment of atopic dermatitis","volume":"11","author":"Seegr\u00e4ber M","year":"2018","unstructured":"Seegr\u00e4ber M, Srour J, Walter A, Knop M, Wollenberg A. Dupilumab for treatment of atopic dermatitis. Expert Rev Clin Pharmacol. 2018, 11:467-74. 10.1080\/17512433.2018.1449642","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1541776","article-title":"Beyond the dichotomy: understanding the overlap between atopic dermatitis and psoriasis","volume":"16","author":"Li M","year":"2025","unstructured":"Li M, Wang J, Liu Q, Liu Y, Mi W, Li W, Li J. Beyond the dichotomy: understanding the overlap between atopic dermatitis and psoriasis. Front Immunol. 2025, 16:1541776. 10.3389\/fimmu.2025.1541776","journal-title":"Front Immunol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert C","year":"2019","unstructured":"Bachert C, Han JK, Desrosiers M, et al.. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019, 394:1638-50. 10.1016\/S0140-6736(19)31881-1","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1159\/000530608","article-title":"Dupilumab-associated psoriasis and psoriasiform manifestations: a scoping review","volume":"239","author":"Su Z","year":"2023","unstructured":"Su Z, Zeng YP. Dupilumab-associated psoriasis and psoriasiform manifestations: a scoping review. Dermatology. 2023, 239:646-57. 10.1159\/000530608","journal-title":"Dermatology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2018.05.014","article-title":"Erythrodermic presentation of psoriasis in a patient treated with dupilumab","volume":"4","author":"Tracey EH","year":"2018","unstructured":"Tracey EH, Elston C, Feasel P, Piliang M, Michael M, Vij A. Erythrodermic presentation of psoriasis in a patient treated with dupilumab. JAAD Case Rep. 2018, 4:708-10. 10.1016\/j.jdcr.2018.05.014","journal-title":"JAAD Case Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/426028-dupilumab-induced-psoriasis-in-a-patient-with-chronic-rhinosinusitis-with-nasal-polyps-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T13:47:55Z","timestamp":1761227275000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/426028-dupilumab-induced-psoriasis-in-a-patient-with-chronic-rhinosinusitis-with-nasal-polyps-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":6,"URL":"https:\/\/doi.org\/10.7759\/cureus.95219","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,23]]}}}